[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"premature-ventricular-complexes\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:premature-ventricular-complexes":25},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,6,0,[8,45,75,98,131,161],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":16,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":23,"conditions":24,"keywords":26,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":33,"lastUpdatePostDateStruct":34,"startDateStruct":37,"completionDateStruct":39,"leadSponsor":41,"locationsCount":44},"100623435","physical-impairments-in-premature-ventricular-complex-100623435",false,"NCT07396597","Physical Impairments in Premature Ventricular Complex","Investigation of Respiratory Functions, Muscle Strength, Physical Activity Level, and Quality of Life in Individuals With Premature Ventricular Complexes","Inclusion Criteria for Individuals with Premature Ventricular Complexes (PVCs):\n\n* Aged between 18 and 80 years\n* Presence of symptomatic premature ventricular complexes resistant to ≥1 antiarrhythmic medication (including β-blockers and calcium channel blockers)\n* Premature ventricular complex burden ≥10%\n* Ventricular arrhythmias originating from any focus within the right or left ventricle\n* Physically able to participate in all study assessments\n* Willingness to participate in the study by providing written informed consent\n\nInclusion Criteria for Control Group Participants:\n\n* Aged between 18 and 80 years\n* Healthy individuals\n* Willingness to participate in the study\n* Physically able to participate in all study assessments\n\nExclusion Criteria for Individuals with Premature Ventricular Complexes (PVCs):\n\n* Left ventricular ejection fraction (LVEF) \\\u003C45% unless PVC-induced cardiomyopathy is documented (defined as a \\>15% improvement in LVEF following reduction of PVC burden through pharmacological therapy or ablation)\n* Progressive decline in LVEF within the last 4 months, regardless of etiology\n* Severe heart failure classified as New York Heart Association (NYHA) Class ≥III\n* Ventricular arrhythmias attributed to underlying structural heart disease, known myocardial scar, or myocarditis\n* Change in the dosage of antiarrhythmic medications (including β-blockers and calcium channel blockers) within 2 months prior to enrollment\n* Failed catheter ablation within 3 months prior to enrollment\n* Known thyroid disorders or individuals undergoing renal dialysis\n* Life expectancy \\\u003C12 months\n* Presence of angina pectoris\n* Diagnosis of chronic obstructive pulmonary disease (COPD) or asthma\n* Resting heart rate \\>120 beats\u002Fmin\n* Resting systolic blood pressure ≥180 mmHg\n* Resting diastolic blood pressure ≥100 mmHg\n* Resting peripheral oxygen saturation ≤90%\n\nExclusion Criteria for Control Group Participants:\n\n* Presence of premature ventricular complexes\n* Presence of any acute or chronic medical condition",true,"ALL","18 Years",{"count":20,"type":21},52,"ESTIMATED","OBSERVATIONAL","Premature ventricular complexes may be observed in individuals without underlying disease due to factors such as physical inactivity, advanced age, smoking, male sex, and psychosocial disturbances, and in some cases may result in sudden cardiac death. Therefore, the aim of this study is to investigate respiratory function, respiratory muscle strength, cough strength, handgrip strength, physical activity level, and quality of life in individuals with premature ventricular complexes.",[25],"Premature Ventricular Complexes",[27,28,29,30,31],"cough","muscle strength","quality of life","pulmonary function","ventricular premature complexes,","NOT_YET_RECRUITING","2026-03-23",{"date":35,"type":36},"2026-03-27","ACTUAL",{"date":38,"type":21},"2026-04-30",{"date":40,"type":21},"2028-03-01",{"name":42,"class":43},"Izmir Democracy University","OTHER",1,{"id":46,"slug":47,"hasResults":11,"nctId":48,"briefTitle":49,"officialTitle":50,"acronym":51,"eligibilityCriteria":52,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":53,"targetDuration":4,"studyType":55,"phases":56,"briefSummary":58,"conditions":59,"keywords":62,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":67,"lastUpdatePostDateStruct":68,"startDateStruct":70,"completionDateStruct":72,"leadSponsor":73,"locationsCount":44},"100627184","catheter-ablation-versus-anti-arrhythmic-drugs-for-premature-ventricular-complexes-100627184","NCT07445334","Catheter Ablation Versus Anti-arrhythmic Drugs for Premature Ventricular Complexes","Catheter Ablation Versus Anti-arrhythmic Drugs for Premature Ventricular Complexes (CAAD-PVC): A Randomised Controlled Trial Pilot Study","CAAD-PVC","Inclusion Criteria:\n\n* Premature ventricular complex burden of at least 10%, as determined by multiday (\\>24-hour) heart rhythm monitoring\n* Normal left ventricular ejection fraction\n* Aged ≥18 years.\n\nExclusion Criteria:\n\n* Unable or unwilling to provide informed consent or comply with study requirements including study investigations and follow-up, medical adherence, completion of intervention.\n* Women who are pregnant or breast feeding.\n* Life expectancy ≤ 12 months.\n* Ventricular tachycardia (VT) that is inducible lasting 10 seconds or more; spontaneously occurring lasting 30 seconds or more or not hemodynamically tolerated); or 10 or more episodes of non-sustained ventricular tachycardia (defined as more than five sequential beats, lasting no more than 10 seconds) in 24 hours during ambulatory heart rhythm recording.\n* Structural heart disease including clinically significant coronary artery, valvular disease or clinically significant myocardial replacement.\n* Known cardiac channelopathies (e.g. Catecholaminergic polymorphic ventricular tachycardia (CPVT), long- or short QT syndrome, Brugada syndrome).\n* Responsible primary care or other responsible physician believes it is not appropriate to participate in the study or unable to complete the study procedures, e.g. concomitant illness, physical impairment or mental condition which could interfere with the conduct of the study including outcome assessments.",{"count":54,"type":21},40,"INTERVENTIONAL",[57],"NA","Premature ventricular complexes (PVCs) are extra, abnormal heart beats arising from the ventricles of the heart and are the most common ventricular arrhythmia. PVCs can be treated with medication or with a procedure called catheter ablation. It is not known which provides a better cure or provides better quality of life. The purpose of this research project is to study the best way to treat PVCs by comparing the use of medication to catheter ablation to assess which approach is better at reducing symptoms and improving quality of life.",[25,60,61],"Premature Ventricular Contraction (PVC)","Premature Ventricular Beats",[63,64,25,65,66],"PVC","catheter ablation","anti-arrhythmic medication","beta blocker","2026-02-24",{"date":69,"type":36},"2026-03-03",{"date":71,"type":21},"2026-03-01",{"date":40,"type":21},{"name":74,"class":43},"Western Sydney Local Health District",{"id":76,"slug":77,"hasResults":11,"nctId":78,"briefTitle":79,"officialTitle":80,"acronym":4,"eligibilityCriteria":81,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":82,"enrollmentInfo":83,"targetDuration":4,"studyType":55,"phases":85,"briefSummary":86,"conditions":87,"keywords":4,"overallStatus":88,"whyStopped":4,"lastUpdateSubmitDate":89,"lastUpdatePostDateStruct":90,"startDateStruct":92,"completionDateStruct":94,"leadSponsor":96,"locationsCount":44},"100394372","taes-for-fpvcs-a-pragmatic-randomized-controlled-trial-100394372","NCT04415203","TAES for FPVCs: a Pragmatic, Randomized Controlled Trial","Efficacy and Safety of Transcutaneous Auricular Vagus Nerve Stimulation for Frequent Premature Ventricular Complexes: A Randomized Controlled Trial","Inclusion Criteria:\n\n* Diagnosed as frequent premature ventricular contractions;\n* 2 ≤ Lown level ≤ 4A;\n* 18 ≤ age ≤ 75;\n* Volunteered to participant\n\nExclusion Criteria:\n\n* Severe valvular disease, congenital heart disease, pericardial disease, hypertrophic cardiomyopathy, unstable angina pectoris, acute myocardial infarction, myocarditis, aneurysm, congestive heart failure decompensation period (NYHA grade III or VI), cardiogenic shock, cerebrovascular disease, hematopoietic system disease, severe mental disease;\n* Bradycardia, including pathologic sinus node syndrome, degree II or greater atrioventricular block;\n* Those who have already had pacemaker or percutaneous coronary intervention, or who plan to have pacemaker or percutaneous coronary intervention;\n* Pregnant or lactating women;\n* Local sensory deficit, or allergic to current;\n* May be allergic to percutaneous patches；\n* Blood pressure ≤ 90\u002F60 mmHg;\n* Those who have participated in other clinical trials within 3 months.","75 Years",{"count":84,"type":21},90,[57],"This prospective, randomized controlled trial aims to evaluate the efficacy and safety of Transcutaneous Auricular Vagus Nerve Stimulation (TAVNS) for patients with frequent premature ventricular coomplexes (FPVCs). Ninety participants will be randomized to TAVNS group and sham-TAVNS group with the ratio of 1:1. They will receive TAVNS plus usual care or sham-TAVNS plus usual care for 6 weeks, and then be followed up for 12 weeks after the treatment. The primary outcome was the proportion of participants with a 50% decrease of the 24 hour (24h) premature ventricular complexes (PVCs) after 6-week treatment. Secondary outcomes include the proportion of participants with a 75% decrease of the 24h-PVCs; the decrease from baseline of 24h-PVCs, total 24h-heartbeat, and the frequency of supraventricular arrhythmia; the score change from baseline in PVCs-related symptoms; the score change from baseline in SAS and SDS. Subgroup analyses will be performed in age, gender, and the severity of PVCs. Safety assessment will be documented during the whole trial.",[25],"RECRUITING","2025-07-16",{"date":91,"type":36},"2025-07-20",{"date":93,"type":36},"2020-06-04",{"date":95,"type":21},"2025-12",{"name":97,"class":43},"Guang'anmen Hospital of China Academy of Chinese Medical Sciences",{"id":99,"slug":100,"hasResults":11,"nctId":101,"briefTitle":102,"officialTitle":103,"acronym":104,"eligibilityCriteria":105,"healthyVolunteers":16,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":106,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":108,"conditions":109,"keywords":115,"overallStatus":88,"whyStopped":4,"lastUpdateSubmitDate":122,"lastUpdatePostDateStruct":123,"startDateStruct":125,"completionDateStruct":127,"leadSponsor":129,"locationsCount":5},"100589079","flecainide-in-idiopathic-premature-ventricular-contractions-and-related-cardiomyopathy-100589079","NCT06949748","Flecainide in Idiopathic Premature Ventricular Contractions and Related Cardiomyopathy","UNIFLECA Study: Prospective Cohort Study on Flecainide's Impact on Persistent High Premature Ventricular Contraction Burden and PVC-Induced Cardiomyopathy","UNIFLECA","Inclusion Criteria:\n\n* Frequent idiopathic PVCs (burden \\>5% on multiple 24-hour Holter ECG recordings)\n* Normal cardiac structure and function on echocardiography\n* No late gadolinium enhancement or myocardial scar on cardiac MRI\n* Normal coronary angiography (excluding ischemic cardiomyopathy)\n* Normal serum electrolytes and renal function\n* Willingness to comply with follow-up schedule and drug titration\n\nExclusion Criteria:\n\n* Structural heart disease\n* Ischemic heart disease (confirmed by angiography)\n* History of sustained ventricular arrhythmias\n* Left ventricular ejection fraction (LVEF) \\\u003C40% at baseline\n* Brugada syndrome, long QT syndrome, or other channelopathies\n* Contraindications to class IC agents\n* Use of concurrent antiarrhythmics or proarrhythmic drugs",{"count":107,"type":21},300,"The UNIFLECA study is a prospective, single-arm, observational cohort evaluating the efficacy, safety, and tolerability of flecainide (in the form of Sanocard) in adults with frequent idiopathic premature ventricular contractions (PVCs) and suspected PVC-induced cardiomyopathy (PVCi-CMP). Frequent PVCs-defined as a burden \\>5% on two separate 24-hour Holter recordings-are increasingly recognized as a cause of reversible systolic dysfunction in patients without structural heart disease.\n\nParticipants undergo a comprehensive baseline evaluation including echocardiography, occasionally cardiac MRI, and coronary angiography or equivalent testing to confirm the absence of structural abnormalities. Patients are enrolled only if they are ineligible or unwilling to undergo catheter ablation, and have no contraindications to flecainide.\n\nFlecainide therapy is initiated at a starting dose of 100 mg\u002Fday and titrated up to 200 mg\u002Fday, guided by ECG findings, symptom response, and QRS duration. Regular follow-up occurs at three-month intervals over three years, with periodic 24-hour Holter monitoring and assessment of symptoms, LVEF, and adverse events.\n\nThe primary outcome is the reduction in PVC burden. Secondary outcomes include improvement in LVEF, symptom relief (measured by structured questionnaires), adverse effects, and long-term treatment adherence. The study aims to generate real-world data on the non-invasive management of PVCs with flecainide and explore its role as an alternative to ablation in carefully selected patients.",[61,25,60,110,111,112,113,114],"Arrhythmia Ventricular","Ventricular Dysfunction, Left","Ventricular Dysfunction","Cardiomyopathies, Secondary","Cardiomyopathies",[116,117,104,118,63,119,120,121],"Flecainide","Sanocard","PVC induced CMP","Premature Ventricular Contraction","Outflow Tract PVC","NonOutflow Tract PVC","2025-06-27",{"date":124,"type":36},"2025-07-02",{"date":126,"type":36},"2024-04-26",{"date":128,"type":21},"2027-12-01",{"name":130,"class":43},"University of Athens",{"id":132,"slug":133,"hasResults":11,"nctId":134,"briefTitle":135,"officialTitle":136,"acronym":137,"eligibilityCriteria":138,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":139,"targetDuration":4,"studyType":55,"phases":141,"briefSummary":142,"conditions":143,"keywords":146,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":152,"lastUpdatePostDateStruct":153,"startDateStruct":155,"completionDateStruct":157,"leadSponsor":159,"locationsCount":44},"100594995","transcutaneous-vagus-nerve-stimulation-for-ventricular-arrhythmias-100594995","NCT07026695","Transcutaneous Vagus Nerve Stimulation for Ventricular Arrhythmias","Transcutaneous Electrical Vagus Nerve Stimulation for Suppression of Ventricular Arrhythmias","TREAT-VT","PVC Cohort\n\nInclusion Criteria:\n\n* Age \\> 18 years old.\n* Participants must understand and be willing to sign a written informed consent document.\n* PVC burden of \\>10% in a 24-hour period on Holter monitoring.\n\nExclusion Criteria:\n\n* Coronary artery disease\n* Known cardiac disease (heart failure or cardiomyopathy) in the documented absence of PVCs. Individuals with suspected PVC-induced cardiomyopathy heart failure, defined as cardiomyopathy or heart failure only diagnosed in the setting of a \\>10% PVC burden, will be allowed to participate.\n* A known diagnosis of Epilepsy.\n* Ongoing pregnancy or intention to become pregnant in the forthcoming 12 months.\n* Participants using a TENS device for any indication\n\nVT cohort\n\nInclusion Criteria:\n\n* Participants with structural heart disease and a transvenous implantable cardioverter defibrillator (ICD) in situ\n* At least three clinically significant VT events (VT events defined as either \\>30 seconds of sustained VT, appropriate ICD ATP therapies or appropriate ICD shocks) in the six months before enrolment\n\nExclusion Criteria:\n\n* Heart failure syndrome with inotrope dependency or requiring mechanical assistance.\n* Reversible cause of arrhythmia (e.g. culprit electrolyte abnormality or toxin)\n* NYHA (New York Heart Association) stage IV heart failure\n* Myocardial infarction or cardiac surgery in the last six months\n* Life expectancy \\\u003C12 months\n* Ongoing pregnancy or intention to become pregnant in the forthcoming 12 months.\n* Participants using a TENS device for any indication",{"count":140,"type":21},72,[57],"Ventricular arrhythmias are abnormal heart rhythms that arise from the bottom chambers of the heart. They can cause debilitating symptoms when they occur intermittently (these are called premature ventricular ectopics or PVCs) and can be life-threatening when they occur continuously (called ventricular tachycardia or VT). These are the most common causes of sudden cardiac death, especially in patients with pre-existing heart disease.\n\nThey can be a result of overactivation of the sympathetic nervous system, and in extreme circumstances, surgery to cut the nerve may be needed. A novel approach to target this nervous system using a transcutaneous electrical nerve stimulator (TENS) machine has successfully treated arrhythmias that come from the top chambers of the heart (atrial fibrillation). An ear clip is applied for an hour per day connected to a device (smaller than a phone) that can activate the parasympathetic nervous system (that counteracts the sympathetic nervous system). This is called Low-Level Tragus Stimulation (LLTS). Because it has been used for epilepsy for decades, we have evidence of a very high safety profile and tolerability. We plan to enrol 72 patients, 34 with many PVCs and 38 with VT, and randomise them to either first receive LLTS or first receive sham treatment (this will appear the same to the patient and researchers but without any meaningful vibrations being emitted in the sham group). Each patient will then swap over to the other treatment. We will compare whether the LLTS reduces the amount of ventricular arrhythmias during compared to the amount during the sham treatment period. We will use Holter monitors to measure the amount of PVCs after each period in the PVC group. VT patients have an implantable defibrillator that continuously monitors for VT episodes in this group. We will only enrol adults who can give informed consent, and study participation will not interfere with a patient's clinical treatment.",[25,144,145],"Ventricular Tachycardia (VT)","Ventricular Arrhythmias",[147,148,149,150,151],"double-blinded","randomized","sham-controlled","crossover","prospective","2025-06-18",{"date":154,"type":36},"2025-06-24",{"date":156,"type":21},"2025-06-15",{"date":158,"type":21},"2027-12-31",{"name":160,"class":43},"University College, London",{"id":162,"slug":163,"hasResults":11,"nctId":164,"briefTitle":165,"officialTitle":165,"acronym":166,"eligibilityCriteria":167,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":168,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":170,"conditions":171,"keywords":177,"overallStatus":88,"whyStopped":4,"lastUpdateSubmitDate":184,"lastUpdatePostDateStruct":185,"startDateStruct":187,"completionDateStruct":189,"leadSponsor":191,"locationsCount":44},"100577703","when-do-we-have-to-perform-cardiac-magnetic-resonance-in-patients-referred-for-premature-ventricular-complexes-by-their-cardiologists-100577703","NCT06801743","WHEN DO WE HAVE to PERFORM CARDIAC MAGNETIC RESONANCE in PATIENTS REFERRED for PREMATURE VENTRICULAR COMPLEXES by THEIR CARDIOLOGISTS","IRMESV","Inclusion Criteria:\n\n* patients with PVC who have performed ECG, Holter ECG and a CMR\n\nExclusion Criteria:\n\n* patient showing opposition tu use his personal data for the reseach,\n* patient unable to express his opposition,\n* patient deprived of liberty,\n* patient with language issues (speaking or writing French)",{"count":169,"type":21},200,"Premature ventricular complexes (PVC) are a common entity affecting approximatively 20% of the general population. It can be discovered incidentally on electrocardiogram (ECG) or associated with symptoms with a wide spectrum from palpitations, chest pain, to syncope.\n\nThe initial and non invasive assessment includes holter ECG monitoring, a transthoracic echocardiography (TTE) and an exercise stress test to rule out structural heart disease (SHD), and referred to as benign or \"idiopathic\" ventricular arrhythmias (IVA).\n\nHowever, these exams may fail to identify subtle myocardial abnormalities such as arrhythmogenic right ventricle dysplasia (ARVD), apical hypertrophic cardiomyopathy, healed myocarditis, ischemic or non-ischemic cardiomyopathies.\n\nCardiac magnetic resonance (CMR) imaging is the gold standard modality to assess regional and global ventricular function. It is also a unique modality to non-invasively detect myocardial edema, myocardial fatty replacement, focal and diffuse fibrosis and could potentially identify SHD in patients with PVC.\n\nHowever, the role of CMR is uncertain, recommended in case of atypical presentation or when the initial assessment can't exclude a cardiomyopathy (recommendations class IIa).\n\nThis study sought to determine whether and when CMR can be performed to provide diagnosis or prognostic information complementary to initial assessment in patients referred for PVC by their cardiologists.",[25,172,173,174,175,176],"Ventricular Arythmias","Cardiac Magnetic Resonance Imaging","Focal or Diffuse Fibrosis","Structural Heart Disease","Idiopathic",[178,179,180,181,182,183],"premature ventricular complexes","ventricular arythmias","cardiac magnetic resonance","focal or diffuse fibrosis","structural heart disease","idiopathic","2025-02-11",{"date":186,"type":36},"2025-02-13",{"date":188,"type":36},"2024-11-27",{"date":190,"type":21},"2026-05",{"name":192,"class":43},"Centre Hospitalier Universitaire, Amiens"]